You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

ZEJULA (niraparib) is the only once-daily oral PARP inhibitor monotherapy approved for first-line platinum responders with advanced ovarian cancer regardless of biomarker status.1-2

Arrow icon

Extended PFS 
regardless of biomarker status vs placebo1

VIEW EFFICACY

Capsules icon

Manageable
safety and tolerability profile3

VIEW SAFETY

AE icon

Individualised starting dose
that can minimise AEs while maintaining efficacy*1,4-7

VIEW STARTING DOSE

Once daily icon

Convenient,
once-daily oral monotherapy1

VIEW DOSING

*This analysis is exploratory in nature and was not powered to detect a statistically significant treatment effect; therefore, results should be interpreted with caution.

ZEJULA indication

*Zejula is indicated for the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy1

DISCOVER THE PRIMA CLINICAL TRIAL

ZEJULA is indicated:1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Footnotes

AE, adverse event; BRCA, breast cancer susceptibility gene; BRCAmut, BRCA mutation; BRCAwt, BRCA wild-type; CR, complete response; FIGO, International Federation of Gynecology and Obstetrics; GSK, GlaxoSmithKline; HRd, homologous recombination deficient; HRp, homologous recombination proficient; MoA, mechanism of action; PARP, poly(ADP-ribose) polymerase; PFS, progression-free survival; PLC, public limited company; PR, partial response; QoL, quality of life.

References

  1. Zejula Summary of Product Characteristics www.medicines.ie Last Accessed October 2023.
  2. Olaparib Summary of Product Characteristics www.medicines.ie Last Accessed October 2023.
  3. González-Martín A, Pothuri B, Vergote I, et al. N Engl J Med. 2019;381(25):2391–2402.
  4. Mirza MR, González-Martin A, Graybill WS, et al. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA/ENGOT­ OV26/GOG-3012 trial. Cancer. 2023;1-10. doi:10.1002/ cncr. 34706.
  5. Korach J, Graybill W, Redondo A, et al. Niraparib in patients with newly diagnosed advanced ovarian BRCAm cancer: a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial. Abstract presented at the European Society of Gynaecological Oncology (ESGO) Congress; 14–16 December 2020. Abstract 571.
  6. GSK, Inc. Data on file. 2020 [list of adverse events by fixed versus individualised starting dose].
  7. GSK, Inc. Data on file. 2020 [Niraparib Global Data Sheet].

 

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Zejula is a registered trademark of the GlaxoSmithKline group of companies.

September 2024 PM-IE-NRP-WCNT-220022